The pathophysiology of the growth plate in juvenile idiopathic arthritis

Rheumatology

Volumn 45, Issue 1, 2006, Pages 11-19

  MacRae, V E ^a,b   Farquharson, C ^a   Ahmed, S F ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CYTOKINE; ESTROGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GLUCOCORTICOID; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; RALOXIFENE; RECOMBINANT GROWTH HORMONE; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSCRIPTION FACTOR SOX9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOLESCENT; APOPTOSIS; BONE GROWTH; CHILDHOOD DISEASE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DRUG MECHANISM; GENE EXPRESSION; GROWTH ACCELERATION; GROWTH DISORDER; GROWTH PLATE; GROWTH RETARDATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG BONE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ARTHRITIS, JUVENILE RHEUMATOID; CYTOKINES; GONADAL STEROID HORMONES; GROWTH DISORDERS; GROWTH HORMONE; GROWTH PLATE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 29844453624     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei091     Document Type: Review

References (130)

1. Grom AA, Murray KJ, Luyrink L et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39:1703-10.
2. Yetgin S, Ozen S, Saatci U et al. Evaluation of tumour necrosis factor alpha, interferon gamma and granulocyte-macrophage colony stimulating factor levels in juvenile chronic arthritis. Rheumatology 1999;38:468-71.
3. Rooney M, Varsani H, Martin K, Lombard PR, Dayer JM, Woo P. Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology 2000;39:432-8.
4. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996;60:563-72.
5. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-15.
6. Kutukculer N, Caglayan S, Aydogdu F. Study of pro-inflammatory (TNF-alpha, IL-1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters. Clin Rheumatol 1998;17:288-92.
7. Wilkinson N, Jackson G, Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child 2003;88:186-91.
8. Yilmaz M, Kendirli SG, Altintas D, Bingol G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001;20:30-5.
9. Farquarson C. Bone growth. In: Scanes CG, ed. Biology of growth of domestic animals. Iowa: Ames, Iowa State Press, 2003:170-85.
10. Kronenberg, HM. Developmental regulation of the growth plate. Nature 2003;423:332-6.
11. Hunziker EB, Schnek RK. Physiological mechanisms adopted by chondrocytes in regulating longitudinal bone growth. J Physiol 1989;44:55-71.
12. Breur GJ, Turgai J, Vanenkevort BA, Farnum CE, Wilsman NJ. Stereological and serial section analysis of chondrocytic enlargement in the proximal tibial growth-plate of the rat. Anat Rec 1994; 239:255-68.
13. Buckwalter JA, Mower D, Ungar R, Schaeffer J, Ginsberg B. Morphometric analysis of chondrocyte hypertrophy. J Bone Joint Surg Am 1986;68A:243-55.
14. Breur GJ, Vanenkevort BA, Farnum CE, Wilsman NJ. Linear relationship between the volume of hypertrophic chondrocytes and the rate of longitudinal bone-growth growth plates. J Orthop Res 1991;9:348-59.
15. Bateman JF, Lamandé SR, Ramshaw JAM. Collagen superfamily. In: Comper WD, ed. Extracellular matrix, Vol. 2. Amsterdam: Harwood Academic Publishers, 1996:22-67.
16. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5:623-8.
17. Hunziker EB, Schenk RK, Cruzorive LM. Quantitation of chondrocyte performance in growth-plate cartilage during longitudinal bone-growth. J Bone Joint Surg Am 1987;69A:162-73.
18. Parfitt AM. Misconceptions (1): Epiphyseal fusion causes cessation of growth. Bone 2002;30:337-9.
19. Nilsson O, Baron J. Fundamental limits on longitudinal bone growth: growth plate senescence and epiphyseal fusion. Trends Endocrinol Metab 2004;15:370-4.
20. Zezulak KM, Green H. The generation of insulin-like growth factor-1-sensitive cells by growth-hormone action. Science 1986; 233:551-3.
21. Isaksson OGP, Jansson JO, Gause IAM. Growth-hormone stimulates longitudinal bone-growth directly. Science 1982;216:1237-9.
22. Hunziker EB, Wagner J, Zapf J. Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in viva. J Clin Invest 1994;93:1078-86.
23. Reinecke M, Schmid AC, Heyberger-Meyer B, Hunziker EB, Zapf J. Effect of growth hormone and insulin-like growth factor I (IGF-1) on the expression of IGF-1 messenger ribonucleic acid and peptide in rat tibial growth plate and articular chondrocytes in viva. Endocrinology 2000;141:2847-53.
24. Smink JJ, Koster JG, Gresnigt MG, Rooman R, Koedam JA, Van Buul-Offers SC. IGF and IGF-binding protein expression in the growth plate of normal, dexamethasone-treated and human IGF-1I transgenic mice. J Endocrinol 2002;175:143-53.
25. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96:7324-9.
26. Yakar S, Rosen CJ, Beamer WG et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110:771-81.
27. Lanske B, Karaplis AC, Lee K et al. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 1996;273:663-6.
28. Weir EC, Philbrick WM, Amling M, Neff LA, Baron R, Broadus AE. Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc Natl Acad Sci USA 1996;93:10240-5.
29. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004; 25:389-425.
30. van der Eerden BCJ, Lowik CWGM, Wit JM, Karperien M. Expression of estrogen receptors and enzymes involved in sex steroid metabolism in the rat tibia during sexual maturation. J Endocrinol 2004;180:457-67.
31. Blanchard O, Tsagris L, Rappaport R, Duval-Beaupere G, Corvol M. Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991;40:711-6.
32. Krohn K, Haffner D, Hugel U, Himmele R, Klaus G, Mehls O, Schaefer F. 1,25(OH)2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calcif Tissue Int 2003;73:400-10.
33. Carani C, Qin K, Simoni Met al. Effect of testosterone and estradiol in a man with aromatase deficiency. New Engl J Med 1997;337:91-5.
34. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-98.
35. Nasatzky E, Schwartz Z, Boyan BD, Soskolne WA, Ornoy A. Sexdependent effects of 17-beta-estradiol on chondrocyte differentiation in culture. J Cell Physiol 1993;154:359-67.
36. Schwartz Z, Nasatzky E, Ornoy A, Brooks BP, Soskolne WA, Boyan BD. Gender-specific, maturation-dependent effects of testosterone on chondrocytes in culture. Endocrinology 1994;134:1640-47.
37. Frank GR. Role of estrogen and androgen in pubertal skeletal physiology. Med Pediatr Oncol 2003;41:217-21.
38. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002;87:93-6.
39. Zak M, Müller J, Karup Pedersen F. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. Horm Res 1999;52:80-5.
40. Simon D, Lucidarme N, Prieur A-M, Ruiz J-C, Czernichow P. Treatment of growth failure in juvenile chronic arthritis. Horm Res 2002;58(Suppl. 1):28-32.
41. Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol 2002;57:185-91.
42. Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoarticular and pauciarticular juvenile rheumatoid arthritis. J Bone Joint Surg Am 1981;63:209-15.
43. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999;42:2330-4.
44. Heuck C, Wolthers OD, Herlin T. Growth-suppressive effect of intra-articular glucocorticoids detected by knemometry. Horm Res 1999;52:95-6.
45. Davies UM, Rooney M, Preece MA, Ansell BM, Woo P. Treatment of growth-retardation in juvenile chronic arthritis with recombinant human growth-hormone. J Rheumatol 1994;21:153-8.
46. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocr Metab 1998;83:403-9.
47. Bechtold S, Ripperger P, Muhlbayer D et al. GH therapy in juvenile chronic arthritis: Results of a two-year controlled study on growth and bone. J Clin Endocr Metab 2001;86:5737-44.
48. Kuhns JG, Swaim LT. Disturbances in growth in chronic arthritis in children. Am J Dis Child 1932;43:1180-3.
49. Ansell BM, Bywaters FGL. Growth in Still's disease. Ann Rheum Dis 1956;15:295-319.
50. De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50.
51. De Benedetti F, Pignatti P, Vivarelli M et al. In viva neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. J Immunol 2001; 166:4334-40.
52. De Benedetti F, Meazza C, Oliveri M et al. Effect of IL-6 on IGF binding protein-3: A study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001; 142:4818-26.
53. Davies UM, Jones J, Reeve Jet al. Juvenile rheumatoid arthritis effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 1997;40:332-40.
54. Tsatsoulis A, Siamopoulou A, Petsoukis C, Challa A, Bairaktari E, Seferiadis K. Study of growth hormone secretion and action in growth-retarded children with juvenile chronic arthritis (JCA). Growth Horm IGF Res 1999;9:143-9.
55. Li P, Schwarz EM. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003;25:19-33.
56. Siegel SA, Shealy D J, Nakada MT et al. The mouse-human chimeric monoclonal-antibody ca2 neutralizes tnf in-vitro and protects transgenic mice from cachexia and tnf lethality in-viva. Cytokine 1995;7:15-25.
57. Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-1 (IGF-1) and IGF-binding proteins by tumour necrosis factor. Am J Physiol 1995;269:1204-12.
58. Barreca A, Ketelslegers JM, Arvigo M, Minuto F, Thissen JP. Decreased acid-labile subunit (ALS) levels by endotoxin in viva and by interleukin-1 beta in vitro. Growth Hormone IGF Res 1998; 8:217-23.
59. Delhanty PJD. Interleukin-1 beta suppresses growth hormone-induced acid-labile subunit mRNA levels and secretion in primary hepatocytes. Biochem Biophys Res Commun 1998;243:269-72.
60. Jones JI, Dercole A J, Camachohubner C, Clemmons DR. Phosphorylation of insulin-like growth-factor (IGF)-binding protein-1 in cell-culture and in viva effects on affinity for IGF-1. Proc Natl Acad Sci USA 1991;88:7481-5.
61. Lang CH, Fan J, Cooney R, Vary TC. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol 1996;270:E430-7.
62. Samstein B, Hoimes ML, Fan J, Frost RA, Gelato MC, Lang CH. IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production. Biochem Biophys Res Commun 1996; 228:611-5.
63. Lang CH, Nystrom GJ, Frost RA. Regulation of IGF binding protein-1 in Hep G2 cells by cytokines and reactive oxygen species. Am J Physiol 1999;276:G719-27.
64. Frost RA, Nystrom GJ, Lang CH. Stimulation of insulin-like growth factor finding protein-1 synthesis by interleukin-1 beta: Requirement of the mitogen-activated protein kinase pathway. Endocrinology 2000;141:3156-64.
65. de Hooge ASK, van de Loo FAJ, Bennink MB et al. Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M - a comparative study in gene-deficient mice. Arthritis Rheum 2003;48:1750-61.
66. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. Interleukin-1 suppresses expression of cartilage-specific type-II and type-IX collagens and increases type-I and type-III collagens in human chondrocytes. J Clin Invest 1988;82:2026-37.
67. Lefebvre V, Peetersjoris C, Vaes G. Modulation by interleukin-1 and tumor necrosis factor-alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta 1990;1052:366-78.
68. Lum ZP, Hakala BE, Mort JS, Recklies AD. Modulation of the catabolic effects of interleukin-1 beta on human articular chondrocytes by transforming growth factor-beta. J Cell Physiol 1996;166:351-9.
69. Bolton MC, Dudhia J, Bayliss MT. Quantification of aggrecan and link-protein mRNA in human articular cartilage of different ages by competitive reverse transcriptase-PCR. Biochem J 1996; 319(pt 2):489-98.
70. Kato Y, Nakashima K, Iwamoto M et al. Effects of interleukin-1 on syntheses of alkaline-phosphatase, type-x collagen, and 1,25-dihydroxyvitamin-d(3) receptor, and matrix calcification in rabbit chondrocyte cultures. J Clin Invest 1993;92:2323-30.
71. Soder O, Madsen K. Stimulation of chondrocyte DNA-synthesis by interleukin-1. Br J Rheumatol 1988;27:21-6.
72. Ikebe T, Hirata M, Koga T. Effects of human recombinant tumor necrosis factor-alpha and interleukin-1 on the synthesis of glycosaminoglycan and DNA in cultured rat costal chondrocytes. J Immunol 1988;140:827-31.
73. Enomoto M, Pan HO, Kinoshita A, Yutani Y, Suzuki F, Takigawa M. Effects of tumor necrosis factor-alpha on proliferation and expression of differentiated phenotypes in rabbit costal chondrocytes in culture. Calcified Tissue Int 1990;47:145-51.
74. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res 2001;19:785-96.
75. Horiguchi M, Akiyama H, Ito H, Shigeno C, Nakamura T. Tumour necrosis factor-alpha up-regulates the expression of BMP-4 mRNA but inhibits chondrogenesis in mouse clonal chondrogenic EC cells, ATDC5. Cytokine 2000;12:5296-301.
76. van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Lowik CWGM. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 2002;61:870-6.
77. Martensson K, Chrysis D, Savendahl L. Interleukin-1 beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004;19:1805-12.
78. Hirano T. Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 1998;16:249-84.
79. Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha and interleukin-6. Lymphokine Cytokine Res 1993;2:2191-223.
80. Nietfeld JJ, Wilbrink B, Helle Met al. Interleukin-l-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990; 33:1695-701.
81. Malfait A-M, Verbruggen G, Veys EM, Lambert J, De Ridder L, Cornelissen M. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol 1994;21:314-20.
82. Guerne PA, Desgeorges A, Jaspar JM et al. Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: Comparison with IL-1. Modulation by dexamethasone. Matrix Biol 1999;18:253-60.
83. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003;27: 2903-12.
84. Horan J, Dean DD, Kieswetter K, Schwartz Z, Boyan BD. Evidence that interleukin-1, but not interleukin-6, affects costochondral chondrocyte proliferation, differentiation, and matrix synthesis through an autocrine pathway. J Bone Miner Res 1996;11:1119-29.
85. Bi WM, Deng JM, Zhang ZP, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet 1999;22:85-9.
86. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem 2000;275:3687-92.
87. Hales DB, Diemer T, Hales KH. Role of cytokines in testicular function. Endocrine 1999;10:201-17.
88. Terranova PF, Rice VM. Review: Cytokine involvement in ovarian processes. Am J Reprod Immunol 1997;37:50-63.
89. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-5.
90. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001;7:1773-81.
91. Chert T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60:2132-5.
92. Taranta A, Brama M, Teti A et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30:368-76.
93. Jilka RL, Hangoc G, Girasole G et al. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 1992;257:88-91.
94. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagas SC. 17 beta-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994;93:944-50.
95. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 1995;15:4971-9.
96. Kurebayashi S, Miyashita Y, Hirose T, Kasayama S, Akira S, Kishimoto T. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. J Steroid Biochem Mol Biol 1997;60:11-7.
97. Cerillo G, Rees A, Manchanda N et al. The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner. J Steroid Biochem Mol Biol 1998;67:79-88.
98. An J, Ribeiro RC, Webb P et al. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci USA 1999;96:15161-6.
99. Evans MJ, Lai K, Shaw LJ, Harnish DC, Chadwick CC. Estrogen receptor alpha inhibits IL-1beta induction of gene expression in the mouse liver. Endocrinology 2002;143:2559-70.
100. Loveridge N, Farquharson C, Scheven BAA. Endogenous mediators of growth. Proc Nutr Soc 1990;49:443-50.
101. Blount S, Crawford A. Regulation of igf-1 receptors on rabbit articular chondrocytes by inflammatory mediators. Agents Actions 1994(Sp. Iss.);41:C177-9.
102. Matsumoto T, Tsukazaki T, Enomoto H, Iwasaki I, Yamashita S. Effects of interleukin-1-beta on insulin-like growth factor-I autocrine/paracrine axis in cultured rat articular chondrocytes. Ann Rheum Dis 1994;53:128-33.
103. Shen WH, Zhou JH, Broussard SR, Freund GG, Dantzer R, Kelley KW. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 2002;62:4746-56.
104. Broussard SR, McCusker RH, Novakofski JE et al. IL-1 beta impairs insulin-like growth factor I-induced differentiation and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. J Immunol 2004;172:7713-20.
105. Strle K, Broussard SR, McCusker RH et al. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 2004;145:4592-602.
106. Hoshi K, Ogata N, Shimoaka T et al. Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage. J Bone Miner Res 2004;19:214-23.
107. Dbaibo GS, El-Assaad W, Krikorian A et al. Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Lett 2001;503:7-12.
108. Memon RA, Holleran WM, Moser AH et al. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscl Thromb Vasc Biol 1998;18:1257-65.
109. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor-necrosis-factor signaling. Cell 1994;78:1005-15.
110. Mathias S, Younes A, Kan CC, Orlow I, Joseph C, Kolesnick RN. Activation of the sphingomyelin signaling pathway in intact el4 cells and in a cell-free system by IL-1-beta. Science 1993;259:519-22.
111. Kanety H, Hemi P, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996;271:9895-7.
112. Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signalling. J Biol Chem 2004;279:34733-40.
113. Krebs DL, Hilton DJ. SOCS proteins: Negative regulators of cytokine signalling. Stem Cells 2001;19:378-87.
114. Turnley AM. Role of SOCS2 in growth hormone actions. Trends Endocrinol Metab 2005;16:53-8.
115. Krebs DL, Hilton DJ. SOCS: Physiological suppressors of cytokine signalling. J Cell Sci 2000;113:2813-9.
116. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrinol Rev 1999;20:501-34.
117. Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K. Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J Neurosci 2004;76:466-74.
118. Martelli AM, Borgatti P, Bortul R et al. Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha. J Bone Miner Res 2000;15:1716 30.
119. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999;13:2905-27.
120. Schubert KM, Scheid MP, Duronio V. Ceramide inhibits protein kinase B/ Akt by promoting dephosphorylation of serine 473. J Biol Chem 2000;275:13330-5.
121. Salinas M, Lopez-Valdaliso R, Martin D, Alvarez A, Cuadrado A. Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 2000;15:156-69.
122. Zinda MJ, Vlahos CJ, Lai MT. Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87MG cells. Biochem Biophys Res Commun 2001;280:1107-15.
123. Zhou HL, Summers SK, Birnbaum MJ, Pittman RN. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J Biol Chem 1998;273:16568-75.
124. Zundel W, Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev 1998;12:1941-6.
125. Meier R, Thelen M, Brian A, Hemmings BA. Inactivation and dephosphorylation of protein kinase Bα (PKBα) promoted by hyperosmotic stress. EMBO J 1998;17:7294-303.
126. Chen D, Fucini RV, Olson AL, Hemmings BA, Pessin JE. Osmotic shock inhibits insulin signaling by maintaining akt protein kinase B in an inactive dephosphorylated state. Mol Cell Biol 1999;19:4684-94.
127. Stratford S, Hoehn KL, Liu F, Summers SA. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 2004; 279:36608-15.
128. von Laue S, Ross RJM. Inflammatory cytokines and acquired growth hormone resistance. Growth Horm IGF Res 2000;10(Suppl. B):9-14.
129. Horvat S, Medrano JF. Lack of Socs2 expression causes the high-growth phenotype in mice. Genomics 2001;72:209-12.
130. Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol 2003;284:G646-54.